Study guide
7.1 Diabetes Management & Counseling
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
7.1 Diabetes Management & Counseling
Key Takeaways Explain This Topic AI
Diabetes is diagnosed by HbA1c ≥6.5%, fasting plasma glucose ≥7.0 mmol/L, or a random glucose ≥11.1 mmol/L with symptoms; asymptomatic results need repeat confirmation on another day.
The general HbA1c target is <7% (53 mmol/mol), relaxed to around <8% in frail or elderly patients and tightened toward <6.5% in young, newly diagnosed patients without hypoglycemia risk.
Metformin remains first-line for type 2 diabetes, but patients with established ASCVD, heart failure, or chronic kidney disease should receive an SGLT2 inhibitor or GLP-1 receptor agonist with proven outcome benefit regardless of baseline HbA1c.
SADMANS sick-day rules: pause SGLT2 inhibitors, ACE inhibitors/ARBs, diuretics, metformin, NSAIDs, and sulfonylureas during dehydrating illness — but never stop insulin.
For Ramadan fasting, stratify risk before the month begins, adjust drug timing and doses, teach more frequent glucose monitoring, and counsel patients to break the fast if glucose falls below 3.9 mmol/L or exceeds 16.7 mmol/L.
Last updated: August 2026
Assessing the Patient: Type 1 vs Type 2 Diabetes
Before building a care plan, confirm which disease you are managing, because the consequences of treatment errors differ completely. Type 1 diabetes mellitus (T1DM) is an autoimmune destruction of pancreatic beta cells; patients are insulin-dependent from diagnosis and stopping insulin — even for one day during illness — risks diabetic ketoacidosis (DKA) . Type 2 diabetes mellitus (T2DM) is progressive insulin resistance with relative insulin deficiency; it is managed stepwise, and insulin is usually a late addition.
- Feature Type 1 Type 2
- Typical onset Childhood/young adult, rapid Adult, insidious (increasingly younger with obesity)
- Body habitus Usually lean Usually overweight/obese
- Ketones/DKA risk High Low (except with SGLT2 inhibitors)
- Insulin Mandatory from diagnosis Optional, added when oral therapy fails
- Diagnostic Criteria
Diagnosis (ADA/WHO-aligned) rests on any one of the following, confirmed on a separate day if the patient is asymptomatic:
- HbA1c ≥6.5% (48 mmol/mol), using a standardized assay
- Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) after ≥8 hours fasting
- 2-hour plasma glucose ≥11.1 mmol/L (200 mg/dL) during a 75 g oral glucose tolerance test
- Random plasma glucose ≥11.1 mmol/L with classic symptoms (polyuria, polydipsia, weight loss)
Remember that HbA1c is unreliable with hemoglobinopathies, recent transfusion, iron-deficiency treatment, or hemolysis — highly relevant in the Gulf region where sickle-cell trait and thalassemia trait are common. Use plasma glucose criteria in those patients.
Individualizing Glycemic Targets
The general HbA1c target is <7% for most non-pregnant adults. Individualize:
Tighter (~<6.5%) : younger patients, short disease duration, no cardiovascular disease, long life expectancy, when achievable without significant hypoglycemia.
Looser (~<8%) : advanced age, frailty, established vascular complications, severe hypoglycemia history, limited life expectancy.
Typical self-monitoring targets paired with an HbA1c <7% are fasting/pre-prandial glucose of 4.4–7.2 mmol/L and peak post-prandial <10 mmol/L .
Guideline-Directed Sequencing
Metformin remains first-line pharmacotherapy for T2DM alongside structured lifestyle intervention (weight loss of 5–10%, ≥150 minutes/week of activity). Check renal function before starting: do not initiate if eGFR <30 mL/min/1.73 m² (contraindicated below 30; review dose between 30–45), and counsel about gastrointestinal upset and long-term vitamin B12 monitoring.
Modern ADA/ESC sequencing selects the add-on by comorbidity, not just HbA1c :
Established ASCVD or high cardiovascular risk → add a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular outcome benefit (e.g., liraglutide, semaglutide, dulaglutide; empagliflozin, canagliflozin, dapagliflozin).
Heart failure or chronic kidney disease (albuminuria) → SGLT2 inhibitor preferred , independent of glucose control.
Weight reduction a priority → GLP-1 receptor agonist or SGLT2 inhibitor; avoid sulfonylureas, thiazolidinediones, and insulin where possible.
Cost-driven → sulfonylurea or pioglitazone are inexpensive but carry hypoglycemia/weight or fluid-retention trade-offs.
Insulin Initiation, Titration, and Injection Technique
When T2DM patients need insulin (typically HbA1c well above target on two or three agents, or symptomatic hyperglycemia), start basal insulin 10 units once daily (or 0.1–0.2 units/kg), titrating by 2 units every 3 days against the fasting glucose target. Continue metformin; review sulfonylureas once prandial insulin is added. T1DM patients need basal-bolus regimens from the start.
Counsel on injection technique at every supply: rotate sites within one region (abdomen absorbs fastest, then arms, thighs, buttocks), keep injections at least 1 cm apart, use 4 mm pen needles for most adults, never reuse needles, and palpate sites for lipohypertrophy — injecting into lumpy tissue causes erratic absorption and unexplained glucose swings.
Monitoring, Hypoglycemia, and Driving
Self-monitoring of blood glucose ( SMBG ) is essential for anyone on insulin or sulfonylureas; continuous glucose monitoring (CGM) is increasingly standard in T1DM and insulin-treated T2DM, with a time-in-range (3.9–10 mmol/L) goal above 70%. Teach a written hypoglycemia action plan: below 4.0 mmol/L , take 15–20 g fast-acting carbohydrate, recheck in 15 minutes, repeat if still low, then follow with a starchy snack if the next meal is distant. Prescribe glucagon for patients at risk of severe hypoglycemia and train a family member to give it. For driving (DVLA-style rules adopted by many Gulf licensing authorities): insulin- and sulfonylurea-treated patients should test before driving and every 2 hours on long journeys, keep glucose above 5 mmol/L ('five to drive'), carry fast-acting carbohydrate in the vehicle, and never drive while hypoglycemic.
Sick-Day Rules, Foot Care, and Ramadan
Teach the SADMANS mnemonic for acute dehydrating illness (vomiting, diarrhea, fever): temporarily stop S GLT2 inhibitors, A CE inhibitors, D iuretics, M etformin, A RBs, N SAIDs, and S ulfonylureas until eating and drinking normally for 24–48 hours. Insulin is never stopped — doses often need increasing during illness with more frequent glucose and ketone monitoring.
Foot care counseling: inspect feet daily, wash and dry between toes, never walk barefoot, check shoes for foreign objects, moisturize dry skin but not between toes, and attend at least annual foot screening with monofilament sensation and pulse checks. Any new ulcer, blister, or color change warrants same-week referral.
Ramadan counseling is core UAE practice. Stratify risk pre-Ramadan (ideally 6–8 weeks before): T1DM, pregnant patients, recent DKA or severe hypoglycemia, and advanced CKD are very high risk and should be advised against fasting or fast only with close supervision. Practical adjustments include moving the morning sulfonylurea dose to iftar and reducing or omitting the daytime dose, continuing metformin/DPP-4 inhibitors largely unchanged, reducing pre-sunset basal or premixed insulin doses by roughly 15–30%, and increasing glucose monitoring — which does not break the fast. Instruct patients to break the fast immediately if glucose falls below 3.9 mmol/L , rises above 16.7 mmol/L , or if symptoms of hypoglycemia or dehydration appear.